Withdrawal and Cancellation of the Financing Plan Using the 10th and 11th Stock Acquisition Rights
First written in FY2017-Q3. 1 of 3 entries say "Dropped", first in FY2017-Q3. Latest entry: FY2019.
0 other companies' latest entry also says "Achieved".
- FY2019AchievedAnnual report
「At a meeting of its board of directors held on 10 June 2019, the company resolved to acquire and cancel all of the 156,350 outstanding units of the 13th stock acquisition rights, and all were cancelled on 27 June 2019.」
All 156,350 unexercised units of the 13th stock acquisition rights were acquired and cancelled, ending the financing plan using those rights. - FY2017RestatedAnnual report
「As of 1 June 2017, all of the 10th and 11th stock acquisition rights remained unexercised, and no funds were allocated from their exercise.」
The full-year report again stated that the 10th and 11th stock acquisition rights remained unexercised and were acquired and cancelled, and that the planned funds were not allocated. - FY2017-Q3DroppedAnnual report
「Because the exercise price of the unexercised portion had diverged from the Company’s current share price and further exercise was not expected, the Board of Directors resolved on 1 June 2017 to acquire all of those stock acquisition rights at their issue price. All of the rights were acquired and cancelled on 15 June of the same year.」
All of the Tenth and Eleventh Stock Acquisition Rights remained unexercised, and the planned allocation of ¥500 million for working capital and ¥1,481,140 thousand for business development of new cell therapy products was not made; all rights were acquired and cancelled.